Physician profile
Benjamin Talley
NPI 1598409484
$857.92
in general payments reported to CMS, 2019-2025
9 companies · $486 in 2025
The $486 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.43 · 2023: $12.99 · 2024: $333 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $236.61 | 2024-2025 | Invega Sustenna, Spravato |
| Janssen Scientific Affairs, LLC | $132.11 | 2025 | |
| Neurocrine Biosciences, INC. | $124.13 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $102.06 | 2024-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $88.43 | 2023-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $68.37 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $54.28 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.50 | 2025 | |
| Lundbeck LLC | $25.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Talley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.